Fecal Calprotectin is a protein that is present in the white blood cells within the intestine. During inflammation, these white blood cells migrate to the intestines and release calprotectin. Fecal calprotectin testing is a laboratory test that measures the amount of calprotectin in the stool. Elevated levels of calprotectin in the stool are indicative of intestinal inflammation, which makes fecal calprotectin testing valuable in diagnosing Inflammatory Bowel Diseases (IBD) like Crohn's disease and ulcerative colitis. The test is more comfortable, non-invasive and accurate compared to endoscopy in screening and monitoring intestinal inflammation.
The global Fecal Calprotectin Test Market is estimated to be valued at Us$ 140.6 Mn in 2023 and is expected to exhibit a CAGR Of 3.9% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing incidences of digestive diseases like IBD is one of the major drivers boosting the growth of the fecal calprotectin test market. According to the Crohn's & Colitis Foundation, in the United States, approximately 3 million people are currently living with IBD - 1 in 250 people have Crohn's disease and 1 in 135 people have ulcerative colitis. These rising disease incidence rates are expected to increase demand for fecal calprotectin tests for early disease diagnosis as well as disease monitoring during treatment.
Another driver fueling the fecal calprotectin test market growth is its non-invasive nature. Since fecal calprotectin tests involve collecting stool samples instead of undergoing invasive endoscopy procedures, they offer more patient convenience and compliance. This has increased the preference and adoption of fecal calprotectin testing among patients and healthcare providers for evaluating intestinal inflammation.
SWOT Analysis
Strength: The fecal calprotectin test market enjoys a strong demand owing to the growing prevalence of inflammatory bowel diseases. The test has high sensitivity and specificity in detecting intestinal inflammation making it a preferred diagnostic tool. It provides an accurate, non-invasive means of assessing intestinal inflammation in a cost-effective manner.
Weakness: The fecal calprotectin test requires collection and transportation of stool samples which some patients may find inconvenient or unhygienic. There is also a lack of awareness among primary care physicians and patients regarding the benefits of this test over traditional diagnostic methods like colonoscopy.
Opportunity: The rising geriatric population suffering from chronic gastrointestinal disorders will drive the need for non-invasive diagnostic tests like fecal calprotectin. Test kit manufacturers are focusing on developing rapid, point-of-care calprotectin assays to provide quicker results and address primary care needs. Home collection test kits with mailed samples are gaining popularity for their ease of use.
Threats: Budget constraints in developing countries limit widespread adoption of fecal calprotectin testing. Strict regulations pertaining to in vitro diagnostic test approvals also pose challenges. Alternative protein-based biomarkers are being researched which could emerge as competitors.
Key Takeaways
The Global Fecal Calprotectin Test Market Demand is expected to witness high growth over the forecast period driven by rising prevalence of inflammatory bowel diseases. Technological advancements are leading to development of rapid, easy-to-use calprotectin test kits catering to needs of primary care settings and home care. The global Fecal Calprotectin Test Market is estimated to be valued at US$ 140.6 M in 2024 and is expected to exhibit a CAGR of 3.9% over the forecast period 2023 to 2030.
Regional analysis: North America currently dominates the fecal calprotectin test market owing to favorable reimbursement policies and increasing awareness about non-invasive diagnostic methods. The rising burden of Crohn's disease and ulcerative colitis in countries like the US and Canada is propelling market growth. Europe is anticipated to witness lucrative opportunities, especially in Germany, UK and France with growing research into calprotectin.
Key players: Key players operating in the fecal calprotectin test market include Thermo Fisher Scientific, Alpco, Axis Shield, biosynex, BÜHLMANN Laboratories, Dragon Laboratory, and Novus Biologicals. Leading manufacturers are investing in expanding their product portfolios with rapid test kits and calibrated calprotectin controls and standards.
Get more insights on this topic :
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian